Thyrocare Bets on Core Pathology Operations, Divests Radiology Arm
What Happened
Thyrocare Technologies has approved the sale of its entire stake in subsidiary Nueclear Healthcare to Trovera Healthcare for about ₹141.4 crore. The transaction will enable the company to exit the radiology and diagnostic imaging business and focus on its core pathology operations.
Key Takeaways
The move reflects Thyrocare’s strategy to concentrate capital and management resources on pathology, while exiting a business that requires significant ongoing investment in equipment and infrastructure. The deal is expected to close by November 2026, subject to approvals.